Samsung BioLogics said that it has implanted a new cell-culturing technology at its third plant, which can shorten its production time by 30 percent.
|Samsung BioLogics headquarters in Songdo, Incheon.|
The technology, called N-1 Perfusion, boosts productivity by increasing cell concentration up to 10 times by simultaneously carrying out cell culture and removing impurities at the N-1 stage, a procedure that comes just before the final cell culture stage for biopharmaceutical products.
Also, the new method can overcome the shortcomings of the conventional way, which had limits in extending the incubation period due to the waste accumulated in the incubator during the cell culture process.
"The introduction of the N-1 perfusion method at a 3,000-liter commercial production site is unheard of even in the contract manufacturing business," the company said. "This is because the risk of protein variation and cell contamination inside the incubator also increases when extending the culture period of the 'N-1' stage."
The company plans to carry out more orders based on its strength in achieving quantitative competitiveness with the world's most extensive production facilities and the successful application of the latest culture technology that accelerates product production, it added.
<© Korea Biomedical Review, All rights reserved.>